Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging

[1]  E. Brunette,et al.  Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging , 2013, Fluids and Barriers of the CNS.

[2]  Peilin Huang,et al.  Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg‐SwDI transgenic mice , 2012, Journal of neurochemistry.

[3]  Nathan T. Ross,et al.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. , 2012, The Journal of clinical investigation.

[4]  Stefan Platzer,et al.  Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease , 2012, PloS one.

[5]  L. Walker,et al.  The role of the ATP-binding cassette transporter P-glycoprotein in the transport of β-amyloid across the blood-brain barrier. , 2011, Current pharmaceutical design.

[6]  H. Kroemer,et al.  Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice , 2011, International journal of Alzheimer's disease.

[7]  Xin Liu,et al.  Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes , 2011, Proceedings of the National Academy of Sciences.

[8]  B. Zlokovic,et al.  Neurodegeneration and the neurovascular unit , 2010, Nature Medicine.

[9]  R. Deane,et al.  Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain , 2010, Journal of neurochemistry.

[10]  T. Veres,et al.  Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies , 2010, British Journal of Cancer.

[11]  H. Kroemer,et al.  MDR1–P‐glycoprotein (ABCB1)‐Mediated Disposition of Amyloid‐β Peptides: Implications for the Pathogenesis and Therapy of Alzheimer's Disease , 2010, Clinical pharmacology and therapeutics.

[12]  Peilin Huang,et al.  ABCG2 reduces ROS‐mediated toxicity and inflammation: a potential role in Alzheimer’s disease , 2010, Journal of neurochemistry.

[13]  Sagar Agarwal,et al.  Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.

[14]  David S. Miller,et al.  Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Disease , 2010, Molecular Pharmacology.

[15]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[16]  I. Romero,et al.  P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  L. Lue,et al.  Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway , 2009, Neurobiology of Disease.

[18]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[19]  E. Brunette,et al.  Dynamic Analysis of the Blood-Brain Barrier Disruption in Experimental Stroke Using Time Domain in Vivo Fluorescence Imaging , 2008, Molecular imaging.

[20]  Matthew P. Frosch,et al.  Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound B , 2008, Annals of neurology.

[21]  John Woulfe,et al.  Cholesterol retention in Alzheimer's brain is responsible for high β- and γ-secretase activities and Aβ production , 2008, Neurobiology of Disease.

[22]  H. Kroemer,et al.  MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier , 2007, Brain pathology.

[23]  Elizabeth M C Hillman,et al.  Optical brain imaging in vivo: techniques and applications from animal to man. , 2007, Journal of biomedical optics.

[24]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[25]  D. Stanimirovic,et al.  The Transport Systems of the Blood–Brain Barrier , 2005 .

[26]  A. Prat,et al.  The Blood-Brain Barrier and Its Microenvironment : Basic Physiology to Neurological Disease , 2005 .

[27]  S. Cole,et al.  Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. , 2005, Toxicology and applied pharmacology.

[28]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[29]  H. Kroemer,et al.  The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. , 2004, Current Alzheimer research.

[30]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[31]  Hong Zhang,et al.  The FASEB Journal express article 10.1096/fj.02-1131fje. Published online September 4, 2003. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels , 2022 .

[32]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[33]  Christiane Kunert-Keil,et al.  Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. , 2002, Pharmacogenetics.

[34]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[35]  T. Wisniewski,et al.  Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. , 2002, Vascular pharmacology.

[36]  J. Bading,et al.  Brain Clearance of Alzheimer's Amyloid-β40 in the Squirrel Monkey: A SPECT Study in a Primate Model of Cerebral Amyloid Angiopathy , 2002, Journal of drug targeting.

[37]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[38]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[39]  J. Bading,et al.  Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy , 1998, Journal of neurochemistry.

[40]  C. Patlak,et al.  Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries , 1996, Journal of neurochemistry.

[41]  B. Zlokovic,et al.  Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs , 1996, Neuroscience Letters.

[42]  L. Rakić,et al.  Transport of Leucine‐Enkephalin Across the Blood‐Brain Barrier in the Perfused Guinea Pig Brain , 1987, Journal of neurochemistry.

[43]  D. Begley,et al.  Blood-brain barrier permeability to leucine-enkephalin,d-Alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine) , 1985, Brain Research.

[44]  F. Calon,et al.  ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. , 2012, Journal of Alzheimer's disease : JAD.

[45]  M. Leissring,et al.  Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.

[46]  E. Brunette,et al.  In vivo optical imaging of ischemic blood-brain barrier disruption. , 2011, Methods in molecular biology.

[47]  G. Farrington,et al.  In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier. , 2011, Methods in molecular biology.

[48]  A. Abulrob,et al.  Integrated platform for brain imaging and drug delivery across the blood-brain barrier. , 2011, Methods in molecular biology.

[49]  D. Berg,et al.  Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease. , 2010, Journal of Alzheimer's disease : JAD.

[50]  Wandong Zhang,et al.  ABC Transporters and Drug Efflux at the Blood-Brain Barrier , 2010, Reviews in the neurosciences.

[51]  H. D. Vries.  fluids and barriers of the CNS , 2010 .

[52]  D. Evanko.  Optical imaging of the native brain , 2009, Nature Methods.

[53]  S. M. Robinson,et al.  Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. , 2009, Journal of Alzheimer's disease : JAD.

[54]  H. Schägger.  Tricine–SDS-PAGE , 2006, Nature Protocols.

[55]  P. Reiner,et al.  beta-Amyloid efflux mediated by p-glycoprotein. , 2001, Journal of neurochemistry.

[56]  B. Zlokovic,et al.  Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. , 1996, Neuroscience letters.